<DOC>
	<DOCNO>NCT02994784</DOCNO>
	<brief_summary>This single arm , open label study design evaluate safety efficacy propylene glycol-free melphalan hydrochloride patient AL amyloidosis . Treatment comprise propylene glycol-free melphalan hydrochloride administer intravenously dose 70-100 mg/m2/day Days -3 -2 condition prior autologous stem cell transplantation .</brief_summary>
	<brief_title>Propylene Glycol-Free Melphalan Hydrochloride ( Evomela ) AL Amyloidosis Patients</brief_title>
	<detailed_description>This single arm , open label study design evaluate safety efficacy propylene glycol-free melphalan hydrochloride patient AL amyloidosis . Treatment comprise propylene glycol-free melphalan hydrochloride administer intravenously dose 70-100 mg/m2/day Days -3 -2 condition prior autologous stem cell transplantation . After give write informed consent , subject evaluate eligibility enrollment study . Baseline evaluation perform outlined Section 7 . Subjects satisfy inclusion exclusion criterion begin study drug . Subjects monitor time medication administration discharge transplant program safety . Organ function hematologic status also measure 6 12 month follow-up visit . Standard response criterion AL amyloidosis hematologic organ response use . Overall response rate measure participant categorize complete response , good partial response , partial response progressive disease . Progression free survival , organ response , safety tolerability propylene glycol-free melphalan hydrochloride assess .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Age 18 year old Eastern Cooperative Oncology Group Performance Status 02 Histologic diagnosis primary systemic ( AL ) amyloidosis base : Deposition amyloid material Congo red stain show characteristic apple green birefringence AND Evidence clonal plasma cell dyscrasia monoclonal protein serum urine immunofixation electrophoresis AND/OR abnormal serum free light chain assay AND/OR clonal plasma cell bone marrow exam demonstrate immunohistochemistry , flow cytometry , situ hybridization AND Evidence organ involvement Eligible treatment high dose melphalan stem cell transplantation per institutional guideline Ability understand willingness sign inform consent Pulmonary Function Test demonstrate diffusion capacity lung carbon monoxide ≥ 50 % Left ventricular ejection fraction ≥40 % Systolic blood pressure &gt; 90 mm Hg ( supine position ) Eastern Cooperative Oncology Group Performance status 2 better ( unless patient diagnose AL amyloidosis involve gastrointestinal peripheral/autonomic nervous system , performance status 3 acceptable ) Previous highdose melphalan stem cell transplant Previous total cumulative dose oral melphalan &gt; 300 mg Cytotoxic chemotherapy within previous 28 day New York Heart Association ≥3 Decompensated uncontrolled heart failure Oxygen dependence epidermal growth factor receptor &lt; 30 ml/min Active infection ( i.e HIV , Hepatitis B C ) Pregnancy breastfeed Exposure another investigational drug within 34 week prior start study treatment Ongoing alcohol drug addiction Unable unwilling comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>